Fig. 2: Kaplan–Meier plots of survival. | Nature Communications

Fig. 2: Kaplan–Meier plots of survival.

From: Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Fig. 2: Kaplan–Meier plots of survival.

a Overall survival in the ITT population; b Progression free survival in the ITT population. c Overall survival in the continuous and non-continuous subgroups of the sintilimab group. Log-rank test stratified by Eastern Cooperative Oncology Group performance-status (ECOG PS) score was used (2-sided).

Back to article page